Breaking News Instant updates and real-time market news.

FB

Facebook

$218.13

3.46 (1.61%)

, V

Visa

$141.45

1.51 (1.08%)

13:19
07/25/18
07/25
13:19
07/25/18
13:19

Notable companies reporting after market close

Notable companies reporting after the market close, with earnings consensus, include Facebook (FB), consensus $1.72... Visa (V), consensus $1.09... PayPal (PYPL), consensus 57c... Gilead Sciences (GILD), consensus $1.56... QUALCOMM (QCOM), consensus 71c... Mondelez (MDLZ), consensus 54c... Las Vegas Sands (LVS), consensus 79c... Vertex Pharmaceuticals (VRTX), consensus 75c... Ford (F), consensus 31c... ServiceNow (NOW), consensus 43c... Align Technology (ALGN), consensus $1.09... O'Reilly (ORLY), consensus $4.06... Xilinx (XLNX), consensus 73c... Mohawk Industries (MHK), consensus $3.90... AMD (AMD), consensus 13c... Equifax (EFX), consensus $1.54... Universal Health Services (UHS), consensus $2.39... Knight-Swift (KNX), consensus 57c... Mattel (MAT), consensus (30c).

FB

Facebook

$218.13

3.46 (1.61%)

V

Visa

$141.45

1.51 (1.08%)

PYPL

PayPal

$91.97

0.55 (0.60%)

GILD

Gilead

$78.19

0.54 (0.70%)

QCOM

Qualcomm

$58.65

-0.21 (-0.36%)

MDLZ

Mondelez

$41.20

-0.31 (-0.75%)

LVS

Las Vegas Sands

$75.66

1.17 (1.57%)

VRTX

Vertex

$175.47

0.66 (0.38%)

F

Ford

$10.16

-0.405 (-3.83%)

NOW

ServiceNow

$187.28

2.4 (1.30%)

ALGN

Align Technology

$379.38

6.88 (1.85%)

ORLY

O'Reilly Automotive

$293.35

-0.71 (-0.24%)

XLNX

Xilinx

$67.84

0.09 (0.13%)

MHK

Mohawk

$218.97

-0.55 (-0.25%)

AMD

AMD

$16.20

0.01 (0.06%)

EFX

Equifax

$128.01

0.84 (0.66%)

UHS

Universal Health

$117.94

3.62 (3.17%)

KNX

Knight-Swift

$35.56

0.76 (2.18%)

MAT

Mattel

$16.30

-0.18 (-1.09%)

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 06

    Aug

  • 13

    Aug

  • 14

    Aug

  • 15

    Aug

  • 15

    Aug

  • 16

    Aug

  • 27

    Aug

  • 10

    Sep

  • 29

    Oct

FB Facebook
$218.13

3.46 (1.61%)

07/23/18
JPMS
07/23/18
NO CHANGE
Target $242
JPMS
Overweight
JPMorgan positive on Facebook into Wednesday's earnings report
JPMorgan analyst Doug Anmuth is positive heading into Facebook's Q2 earnings report on July 25. He believes that both user engagement and monetization have "remained strong," despite data security concerns and Europe's General Data Protection Regulation. The analyst's industry checks suggest Facebook continues to see strong demand from a large and growing advertiser base and that return on investment "remains very compelling." Anmuth keeps an Overweight rating on the shares with a $242 price target.
07/20/18
STFL
07/20/18
NO CHANGE
Target $242
STFL
Buy
Facebook price target raised to $242 ahead of earnings at Stifel
Stifel analyst Scott Devitt is predicting "modest" revenue growth deceleration to 45% growth year-over-year in Q2 from Facebook when it reports next Wednesday, July 25. Across his coverage, he is shifting his view to incrementally favor mega cap U.S. digital advertising over e-commerce outside of China in the near-term as digital advertising growth momentum continues and he sees the potential for multiple expansion. Devitt keeps a Buy rating on Facebook and raised his price target on the stock to $242 from $202.
07/20/18
MKMP
07/20/18
NO CHANGE
Target $255
MKMP
Buy
Facebook expected Q2 expense ramp may be too aggressive, says MKM Partners
MKM Partners analyst Rob Sanderson is keeping his Buy rating and $255 price target on Facebook (FB) ahead of its results next week, saying he expects revenue upside and believes that the anticipated ramp in expenses implied in the consensus for earnings may be too aggressive. The analyst also cites greater visibility on monetization and opportunities in WhatsApp and Messenger justifying a higher multiple, which he sees at a full 3-point discount relative to Google (GOOGL) in spite of Facebook's much higher rate of growth.
07/25/18
BMOC
07/25/18
NO CHANGE
Target $210
BMOC
Market Perform
Facebook price target raised to $210 from $170 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Facebook to $210 after his "deep dive" into the company's main platform and Instagram advertising revenue and format, estimating a $52.8B 2018 advertising revenue generation from the two. The analyst also forecasts a 3-year annualized growth for Facebook at 23% and Instagram at 80% as part of his analysis, driven by the increasing adoption of video ad format in advertising placement. Salmon keeps his Market Perform rating on Facebook, citing "growing costs necessary for content to drive TV budgets to the platform, R&D spending on tools to both manage user data and monitor content, a lack of visibility into monetization at Messenger/WhatsApp, and the emergence of Amazon's (AMZN) advertising business."
V Visa
$141.45

1.51 (1.08%)

07/25/18
ATLE
07/25/18
DOWNGRADE
Target $82
ATLE
Neutral
TransUnion downgraded to Neutral on valuation at Atlantic Equities
As previously reported, Atlantic Equities analyst Kunaal Malde downgraded TransUnion (TRU) to Neutral from Overweight, stating that he sees clear upside potential to Street estimates following another strong quarterly report, but that he also believes the upside is factored into the stock at its current valuation. With less upside seen to buyside estimates, Malde said he prefers other stocks that can deliver similar earnings growth and arguably more sustainably, such as Visa (V). However, he raised his price target on TransUnion shares to $82 from $77.
07/24/18
RAJA
07/24/18
INITIATION
Target $165
RAJA
Outperform
Visa resumed with an Outperform at Raymond James
Raymond James resumed coverage on Visa with an Outperform and $165 price target.
07/19/18
MSCO
07/19/18
NO CHANGE
MSCO
Morgan Stanley upgrades Payments and Processing industry to Attractive
Morgan Stanley analyst James Faucette upgraded his view of the Payments and Processing industry to Attractive, citing the firm's U.S. Strategy Team's call for rotation out of Technology and his view that Payments will be seen as an attractive option for investors looking to become more defensive. Investors underappreciate the resilience of consumer spending and Faucette sees the potential for his Payments coverage market-cap weighted earnings growth to accelerate organically to 15% over 2018-2020 from 11% growth over the last three years, he tells investors. In the group, the firm has Overweight ratings on Visa (V), MasterCard (MA), PayPal (PYPL), GreenSky (GSKY), Worldpay (WP) and FleetCor (FLT). Morgan Stanley has Underweight ratings on Western Union (WU) and On Deck Capital (ONDK), having downgraded On Deck this morning.
07/17/18
WOLF
07/17/18
INITIATION
Target $172
WOLF
Outperform
Visa initiated with an Outperform at Wolfe Research
Wolfe Research analyst Darrin Peller initiated Visa with an Outperform and $172 price target.
PYPL PayPal
$91.97

0.55 (0.60%)

07/24/18
FBCO
07/24/18
NO CHANGE
Target $100
FBCO
Outperform
PayPal has 'unique' opportunity to leverage position, says Credit Suisse
Credit Suisse analyst Paul Condra is increasingly convinced PayPal (PYPL) has a "unique" opportunity to leverage its position as part of the fabric of the online economy, specifically the non-Amazon (AMZN) economy, to become much more valuable to both consumers and merchants. Condra believes PayPal has not leveraged the customer side of its platform to its full potential. While shoppers use it to pay for things, they do not use it to look for things, and herein lies the opportunity, he contends. The analyst reiterates an Outperform rating and $100 price target on PayPal shares.
07/23/18
FBCO
07/23/18
NO CHANGE
FBCO
Outperform
PayPal has 'unique opportunity' to leverage customer base, says Credit Suisse
Credit Suisse analyst Paul Condra believes PayPal (PYPL) has a "unique opportunity" as merchants are increasingly pressured to find ways to differentiate from Amazon (AMZN). PayPal has not leveraged the customer side of its platform to its full potential, Condra tells investors in an intraday research note titled "PayPal Prime? Considering PYPL's Potential." The analyst argues that PayPal can become much more valuable to both consumers and merchants once it leverages its 200M global user base. He keeps an Outperform rating on the shares.
07/19/18
FBCO
07/19/18
NO CHANGE
Target $100
FBCO
Outperform
PayPal price target raised to $100 from $93 at Credit Suisse
Credit Suisse analyst Paul Condra raised his price target for PayPal to $100 from $93 as he remains positive on the name and views its unfolding acquisition strategy as strengthening the core merchant platform and expanding the company's value proposition. The analyst views this strategy as helping PayPal to become a partner of choice for merchants while expanding its offering well beyond payment solutions to include a diverse offering of marketing and sales conversion tools as well as financing options. The iZettle acquisition will also extend the company's reach into brick-and-mortar commerce, he contends, while reiterating an Outperform rating on the shares.
07/25/18
KEYB
07/25/18
NO CHANGE
Target $100
KEYB
Overweight
PayPal price target raised to $100 from $95 at KeyBanc
KeyBanc analyst Josh Beck raised his price target for PayPal to $100 from $95 as his consumer survey indicated the preference for checking out with Venmo doubled sequentially. The analyst notes that the new marquee Pay with Venmo partners like Uber and GrubHub alone create a $30B-plus TPV opportunity next year, suggesting Pay with Venmo may be poised to break out. Separately, his Key First Look Data: Consumer Spending points to a modest sequential acceleration in TPV, which would be above Beck's estimate. He reiterates an Overweight rating on the shares.
GILD Gilead
$78.19

0.54 (0.70%)

07/02/18
ROTH
07/02/18
NO CHANGE
Target $22
ROTH
Buy
Cryoport price target raised to $22 from $12.50 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for Cryoport (CYRX) to $22 from $12.50 while reiterating a Buy rating on the shares. The analyst notes that the European Medicines Agency recommended "marketing authorizations" for therapies developed by two of Cryoport's clients, Gilead's (GILD) Yescarta and Novartis' (NVS) Kymriah. Baldry believes these two approvals roughly double the addressable market for the therapies and offer upside potential to our 2019 forecasts.
06/29/18
ROTH
06/29/18
NO CHANGE
Target $22
ROTH
Buy
Cryoport price target raised to $22 from $12.50 at Roth Capital
Roth Capital analyst Richard Baldry reiterated a Buy rating on Cryoport (CYRX) and raised his price target to $22 from $12.50 after the EMA this morning recommended "marketing authorizations" for Gilead's (GILD) Yescarta and Novartis' (NVS) Kymriah, therapies developed by two of Cryoport's clients. In a research note to investors, Baldry said he believes the two approvals roughly double the addressable market for the therapies and offer upside potential to 2019 forecasts and sees further commercial approvals as likely.
06/29/18
WBLR
06/29/18
NO CHANGE
WBLR
Outperform
Cambrex risk/reward compelling for patient investors, says William Blair
Shares of Cambrex (CBM) are down roughly 5% since reporting softer Q1 results in early May, William Blair analyst John Kreger tells investors in a research note. The analyst expects a stronger Q2 relative to Q1, which he believes should keep the full-year outlook on track. Further, his sum-of-the-parts analysis indicates that Cambrex is reasonably valued even if the Gilead (GILD) business continues to decline quickly. Kreger calculates Cambrex's base business, excluding hepatitis C revenues from Gilead, is currently valued at 11.3 times his 2019 EBITDA estimate. This is a "meaningful" discount to both its public and private peers, which have garnered deal multiples in the 13-14 times range, the analyst points out. He believes the stock's risk/reward profile is "compelling for investors willing to be patient." Kreger reiterates an Outperform rating on Cambrex.
06/28/18
06/28/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CBS (CBS) initiated with an Outperform at Imperial Capital. 2. Limoneira (LMNR) initiated with a Buy at Stifel. 3. Keryx (KERX) initiated with a Buy at H.C. Wainwright. 4. Zosano Pharma (ZSAN) initiated with a Buy at BTIG. 5. Gilead (GILD) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
QCOM Qualcomm
$58.65

-0.21 (-0.36%)

07/23/18
DBAB
07/23/18
NO CHANGE
Target $60
DBAB
Hold
Qualcomm price target raised to $60 from $55 at Deutsche Bank
Deutsche Bank analyst Ross Seymore raised his price target for Qualcomm (QCOM) shares to $60 after concluding that removal of the uncertainty from the NXP Semiconductors (NXPI) deal likely leads to incremental upside in either scenario. The analyst says he has no way of assigning probabilities of deal approval given the politically charged nature of the pending regulatory ruling from China's State Administration for Market Regulation. This week holds a number of significant catalysts/risks for both companies as the purchase agreement deadline and Qualcomm's Q3 earnings report are on Wednesday, Seymore tells investors in a research note. Seymore keeps Hold ratings on both Qualcomm and NXP.
07/23/18
MSCO
07/23/18
NO CHANGE
MSCO
Tariff uncertainty a potential risk to semiconductor demand, says Morgan Stanley
Morgan Stanley analyst Joseph Moore said the firm's quarterly survey of distributors leads him to expect "solid" Q2 results and Q3 guidance from broad-based semiconductor companies this earnings season as demand remains strong. However, the present tariff related uncertainty present a risk for a "demand shock" that could lead to an inventory unwind in the semi supply chain, Moore warns investors. He thinks the potential of further semi stock outperformance is limited at this stage of the cycle, while "even the slightest whiff on the demand front" could lead to a significant decline in stocks, he tells investors. Moore added that he favors companies with more defensive characteristics, such as Analog Devices (ADI), over those with more commodity exposure and lower margins, like Cypress Semiconductor (CY). Other publicly traded companies in the semiconductors space include Micron (MU), AMD (AMD), Intel (INTC), Marvell (MRVL), Microchip (MCHP), Nvidia (NVDA), Qualcomm (QCOM) and Texas Instruments (TXN). Shares of Micron are down 2.5% in pre-market trading to $53.65.
07/23/18
07/23/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. STIFEL SAYS SELL PAPA JOHN'S: Stifel analyst Chris O'Cull downgraded Papa John's (PZZA) to Sell from Hold and cut his price target for the shares to $38 from $50. The outlook for Papa John's is "growing dimmer" after recent media reports indicated a "fraternal corporate culture," O'Cull told investors. The reports reinforce the consumer perception that Papa John's is not a trusted brand, the analyst added. His recent channel checks indicate the company's domestic same-restaurant-sales are running down in the mid-teens since last week's media report about the company's founder using a racial slur. Papa John's is in a "precarious position," as it needs a "strategic savior" but is struggling to find one "willing to underwrite a transaction given the brand damage," O'Cull contended. Papa John's shares are down 7% in midday trading BTIG SAYS BUY SPOTIFY: BTIG analyst Rich Greenfield initiated Spotify (SPOT) with a Buy rating and a price target of $230, saying that awaiting a better entry on the stock price "has not worked." The analyst contended that the company will be a "long-term winner" in the subscription music category that remains in its infancy and will "grow significantly for years to come." DEUTSCHE RAISES QUALCOMM TARGET TO $60: Deutsche Bank analyst Ross Seymore raised his price target for Qualcomm (QCOM) shares to $60 from $55 after concluding that removal of the uncertainty from the NXP Semiconductors (NXPI) deal likely leads to incremental upside in either scenario. The analyst said he has no way of assigning probabilities of deal approval given the politically charged nature of the pending regulatory ruling from China's State Administration for Market Regulation. Seymore kept Hold ratings on both Qualcomm and NXP. ARGUS CUTS GE TO HOLD: Argus analyst John Eade downgraded General Electric (GE) to Hold from Buy, saying that despite his expectations of a turnaround, Q2 results were a "step in the opposite direction" suggesting the company will struggle to meet its FY18 guidance. Eade lowered his FY18 EPS forecast to 97c from $1.03, adding that GE will need to show at least two quarter of progress before he would reconsider his rating. The analyst prefers other large industrials such as Illinois Tool Works (ITW), United Technologies (UTX) and Boeing (BA) over General Electric, he added.
07/24/18
MZHO
07/24/18
NO CHANGE
MZHO
Qualcomm, NXP deal seems headed for a breakup, says Mizuho
Barring an 11th hour approval, Qualcomm's (QCOM) proposed acquisition of NXP Semiconductors (NXPI) is headed for a breakup, Mizuho analyst Vijay Rakesh tells investors in a research note. The analyst says his firm's arbitrage desk sees only a 22% probability of the deal happening.
MDLZ Mondelez
$41.20

-0.31 (-0.75%)

05/15/18
BOFA
05/15/18
NO CHANGE
BOFA
Mondelez, Fluor added to US 1 List at BofA/Merrill
04/16/18
FBCO
04/16/18
NO CHANGE
Target $48
FBCO
Outperform
Mondelez price target lowered to $48 from $53 at Credit Suisse
Credit Suisse analyst Robert Moskow lowered his price target for Mondelez to $48 from $53 on valuation. The analyst reiterates an Outperform rating on the shares.
07/16/18
RBCM
07/16/18
NO CHANGE
Target $51
RBCM
Outperform
Mondelez price target lowered to $51 from $54 at RBC Capital
RBC Capital analyst David Palmer lowered his price target on Mondelez to $51 ahead of its Q2 results next week, citing the adverse FX rate impact against the Euro and the Pound since April. Palmer adds that the quarter may be pressured by higher input costs and the reversal of last quarter's Easter timing benefits, but still expects "strong margin acceleration" in the second half of the year on positive comparison from last year because of the 2017 malware incident and better gross margins from lower cocoa prices. The analyst keeps his Outperform rating on Mondelez.
06/07/18
WELS
06/07/18
NO CHANGE
WELS
J.M. Smucker risk/reward not positive amid selloff, says Wells Fargo
In a post-earnings research note titled "We'd Abstain From Buying Into Weakness," Wells Fargo analyst John Baumgartner recommends not buying the dip today in shares of J.M. Smucker (SJM). The stock does not offer a positive risk/reward given the "shaky outlooks" for coffee and pet revenue growth in fiscal 2019, Baumgartner tells investors. Further, the analyst thinks Smucker's free cash growth will prove weaker into fiscal 2020 with inflation biased to the upside. For investors seeking free cash flow yield, the analyst prefers Post Holdings (POST). For investors seeking growth, Baumgartner continues to recommend Mondelez (MDLZ). He keeps a Market Perform rating on J.M. Smucker.
LVS Las Vegas Sands
$75.66

1.17 (1.57%)

07/02/18
07/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Canon (CAJ) downgraded to Sell from Neutral at Goldman Sachs with analyst Satoru Ogawa recommending a cautious stance on the Japanese precision equipment sector due to "high valuations and flagging earnings momentum." 2. Integra LifeSciences (IART) downgraded to Neutral from Buy at Citi with analyst Amit Haza saying he sees limited upside following the recent rally in the shares. 3. Nevro (NVRO) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Lewis stating that Nevro's commercial message on clinically superiority has not resonated and competitors have gained traction, blunting the company's share gains. 4. Nordstrom (JWN) downgraded to Market Perform from Outperform at Cowen with analyst Oliver Chen citing the stock's current valuation after its recent run, his view of a likely lack of near-term upside to full-line sales and store traffic, and the need for improvements at the Rack division. 5. Las Vegas Sands (LVS) downgraded to Neutral from Buy at BofA/Merrill with analyst Shaun Kelley saying June was the second month of weaker than expected GGR growth, there are continued mixed reads from the firm's Macau Macro Activity Tracker, and weaker FX and trade fears have increased uncertainty. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/02/18
BOFA
07/02/18
DOWNGRADE
Target $80
BOFA
Neutral
Las Vegas Sands downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Shaun Kelley downgraded Las Vegas Sands to Neutral and cut its price target to $80 from $85. The analyst said June was the second month of weaker than expected GGR growth, there are continued mixed reads from the firm's Macau Macro Activity Tracker, and weaker FX and trade fears have increased uncertainty.
07/05/18
MSCO
07/05/18
NO CHANGE
MSCO
Pullback in Macau gaming names a buying opportunity, says Morgan Stanley
Morgan Stanley analyst Thomas Allen believes the recent selloff in Macau gaming stocks is overdone, as he contends the fact that Macau's gaming revenue growth has missed on the headline for two months in a row is attributable to rising expectations, foreign exchange impacts and likely an improper factoring in of seasonality and the World Cup. Q2 gross gaming revenue growth of 17.2% still beat his forecast of 16%, noted Allen, who said Las Vegas Sands (LVS) continues to be his favored gaming name. He also has an Overweight rating on MGM Resorts (MGM). Allen keeps an Equal Weight rating on Wynn Resorts (WYNN), but sees the stock becoming increasingly attractive if Macau is still "very healthy," as he suspects.
07/20/18
MSCO
07/20/18
NO CHANGE
MSCO
MGM Resorts forecast lowered at Morgan Stanley to account for Macau share loss
Morgan Stanley analyst Thomas Allen, in his preview of Q2 results for the Gaming names he covers, noted that Macau GGR increased 17% in Q2, which was above his estimate of 16% growth. He also said he expects Las Vegas has had a "relatively good" quarter, noting RevPAR in April-May was up 6% and June has a "relatively easy" comparison. Allen lowered his Q2 consolidated property EBITDA estimate for MGM Resorts (MGM) by 2%, factoring in more share loss at the Peninsula property and worse hold as well as lower MGM Cotai EBITDA, and he lowered his price target on MGM to $38 from $39. He raised his Q2 consolidated property EBITDA estimate for Las Vegas Sands (LVS) by 1% and keeps an $86 price target on the stock. He raised his Q2 property EBITDA view for Wynn (WYNN) by 3% and keeps a $200 price target on its shares. Allen has Overweight ratings on Las Vegas Sands and MGM and an Equal Weight rating on Wynn Resorts.
VRTX Vertex
$175.47

0.66 (0.38%)

07/16/18
JEFF
07/16/18
NO CHANGE
Target $210
JEFF
Buy
Vertex price target raised to $210 from $195 at Jefferies
Jefferies analyst Michael Yee raised his price target for Vertex Pharmaceuticals to $210 saying he wants to own the stock as a "top large cap idea." The analyst expects good Q2 results on July 25 and ramp of new cystic fibrosis drug Symdeko. He believes 2019 consensus estimates are too low given that the triple pill could start in 2019. Yee keeps a Buy rating on Vertex.
06/29/18
RBCM
06/29/18
NO CHANGE
Target $94
RBCM
Sector Perform
Galapagos NV price target lowered to $94 from $100 at RBC Capital
RBC Capital analyst Brian Abrahams lowered his price target on Galapagos (GLPG) to $94 and kept his Sector Perform rating after the company's phase 2 trial data for '2737 suggested that it will be hard for it to compete with Vertex (VRTX) in Cystic fibrosis. Abrahams says he is removing the CF value from his model, even though he sees some support for the stock price from the program's "modest expectations" ahead of the trial and the promise of its lead asset filgotinib.
06/29/18
COWN
06/29/18
NO CHANGE
COWN
Outperform
Galapagos trial disappointment positive for Vertex, says Cowen
Cowen analyst Phil Nadeau noted Galapagos (GLPG) reported its first efficacy data for its drug candidate GLPG2737. The drug produced improvements in lung function and sweat chloride, but those results were well below those produced by Vertex's (VRTX) C2 correctors, implying that Galapagos is unlikely to be competitive. The results are positive for Vertex, which remains a top large cap pick for it CF franchise, said Nadeau. He reiterated his Outperform rating and $200 price target on Vertex and maintained his Outperform rating on Galapagos.
07/16/18
WBLR
07/16/18
NO CHANGE
WBLR
Market Perform
Vertex fair value estimate raised to $174 from $145 at William Blair
William Blair analyst Y. Katherine Xu raised her fair value estimate for Vertex Pharmaceuticals to $174 and keeps a Market Perform rating on the shares. The analyst increased Vertex's initial market share and equilibrium share in the cystic fibrosis market from 80% to 90%, and from 60% to 80%, respectively, based on timeline delays in competitors' development. She continues to assign probability of success to a Vertex triple combo at 85%.
F Ford
$10.16

-0.405 (-3.83%)

07/20/18
JPMS
07/20/18
NO CHANGE
JPMS
Overweight
JPMorgan says buy GM, sell Tesla into Q2 earnings reports
JPMorgan analyst Ryan Brinkman forecasts lower than consensus Q2 earnings for Ford (F) and higher than Street earnings for General Motors (GM). Both companies are likely to be impacted by higher commodity costs during the quarter, although the decline in spot prices subsequent to the quarter should limit impact to the full year, Brinkman tells investors in a research note previewing the Q2 earnings for the automakers. The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintains Overweight ratings on GM and Ford, with a preference for GM shares. He also keeps his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
07/24/18
PIPR
07/24/18
NO CHANGE
Target $57
PIPR
Overweight
General Motors outperforming Ford in China, says Piper Jaffray
While both would suffer in a trade war, it is clear that General Motors (GM) is outperforming Ford (F) in China, Piper Jaffray analyst Alexander Potter tells investors in a research note. The analyst views GM's China business as stable, with a growing presence in luxury. He thinks Cadillac represented 16.7% of GM's Q2 revenue in China, versus 13.6% in 2017, which should boost margins. Until its "new product blitz gains momentum, Ford's China business will likely continue bleeding," Potter contends. He notes the company's Ford's retail sales in China declined by 38% year-over-year in June. The analyst keeps an Overweight rating on GM and a Neutral rating on Ford.
07/13/18
GSCO
07/13/18
DOWNGRADE
Target $142
GSCO
Neutral
Visteon downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst David Tamberrino downgraded Visteon (VC) to Neutral from Buy, citing potential near-term risks given its high exposure to Ford (F), high 2019 consensus revenue growth expectations, and risk for its DriveCore AV/ADAS platform. Tamberrino, who thinks 2019 may be a "gap year" for revenue growth, cut his price target on Visteon shares to $142 from $150.
07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
NOW ServiceNow
$187.28

2.4 (1.30%)

07/02/18
SBSH
07/02/18
NO CHANGE
Target $200
SBSH
Buy
ServiceNow price target raised to $200 from $174 at Citi
Citi analyst Walter Pritchard raised his price target for ServiceNow to $200 after exploring avenues for the company to expand its total addressable market. The analyst sees "viable paths" for both organic investment and potential for up-tick in acquisitions. He believes ServiceNow has "ample medium-term market opportunity" to keep current growth sustained, mostly driven organically. The company's path to $4B in revenue is within sight with multi-product organic growth drivers, Pritchard tells investors in a research note titled "Plotting the Path Toward $10B in Revenue." The analyst keeps a Buy rating on the shares.
07/20/18
PIPR
07/20/18
NO CHANGE
Target $210
PIPR
Overweight
ServiceNow price target raised to $210 from $190 at Piper Jaffray
Piper Jaffray analyst Alex Zukin raised his price target for ServiceNow to $210 ahead of the company's Q2 results on July 25. The analyst, based on his channel checks, expects a "very strong" from ServiceNow. Checks suggest that ServiceNow's Q2 was ahead of internal expectations and "much better" than Q1, Zukin tells investors in a pre-earnings research note. He continues to believe the company is well positioned longer term and reiterates an Overweight rating on the shares.
06/15/18
SBSH
06/15/18
DOWNGRADE
Target $98
SBSH
Sell
Citi downgrades Splunk to Sell on 'plateauing' growth drivers
Citi analyst Walter Pritchard downgraded Splunk (SPLK) to Sell from Neutral with an unchanged price target of $98. The stock in premarket trading is down 4%, or $4.72, to $114.78. The analyst sees "growth drivers plateauing" and "some warning signs in numbers." Splunk is facing increasing competition, adoption challenges caused by a "persistently unconventional" pricing model and market share in security nearing levels where others have had challenge breaking through, Pritchard tells investors in a research note. Further, he believes the stock is "vulnerable" with a valuation in-line with high-growth software-as-a-service app players. The analyst recommends Salesforce (CRM) and Salesforce (NOW) or security peer Palo Alto Networks (PANW) over Splunk (SPLK).
07/20/18
OPCO
07/20/18
NO CHANGE
OPCO
Perform
ServiceNow shares look fully valued after 'strong' run-up YTD, says Oppenheimer
Oppenheimer analyst Brian Schwartz maintained a Perform rating on ServiceNow (NOW) ahead of the company's Q2 results on July 25, which he views as "solid." In a research note to investors, Schwartz says he thinks the shares look fully valued after a "strong" run-up year-to-date, adding that the tone from industry checks and June's visit to headquarters sounded "positive," but that the medium-term growth and margin framework remains uncertain. The analyst continues to recommend Salesforce (CRM) as the better play in the second half of the year.
ALGN Align Technology
$379.38

6.88 (1.85%)

07/20/18
PIPR
07/20/18
NO CHANGE
Target $425
PIPR
Overweight
Align Technology price target raised to $425 from $325 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Align Technology to $425 after refreshing his analysis on new competition. The analyst continues to believe that competition will not dampen Align's growth profile. He says competing products are not as comprehensive and carry less of a discount to Invisalign than he previously assumed. Further, O'Brien thinks the market opportunity for clear aligners can grow larger than many investors realize. The analyst is confident that Align can sustainably grow sales 20%-30% for multiple years. He encourages investors to build positions, "even at current levels," and reiterates an Overweight rating on the shares.
07/18/18
GSCO
07/18/18
NO CHANGE
Target $43
GSCO
Sell
Dentsply Sirona and Patterson Companies guidance at risk, says Goldman Sachs
Goldman Sachs analyst Robert Jones kept his Sell rating on Dentsply Sirona (XRAY) and Patterson Companies (PDCO) while lowering his price target on the former to $43 from $45 and keeping that of the latter at $21. Jones says his Q2 dental survey indicates a "modest softening in consumable purchases and a slightly greater slowdown in equipment spending" reported by U.S. dentists, which puts the guidance of those companies at risk. The survey also revealed that the outlook for dental specialties lik implants and ortho is still more robust, suggesting a mid-single-digit implant market growth rate. The analyst is also positive on Align Technology (ALGN), keeping its Buy rating and raising its price target to $440 from $344 amid the "strong worldwide growth in 'Invisalign' search data" and the continued rollout of iTero in China.
07/02/18
SPHN
07/02/18
NO CHANGE
Target $265
SPHN
Equal Weight
Align Technology chancery court victory not a surprise, says Stephens
Stephens analyst Chris Cooley said he was not surprised that a chancery court of Tennessee ruled to deny SmileDirectClub's request for a temporary injunction to stop Align Technology from opening new Invisalign Stores. He continues to view Align as the undisputed industry leader regardless of SmileDirectClub's litigation, though Cooley keeps an Equal Weight rating on the shares, citing valuation. He has a $265 price target on Align Technology.
06/26/18
NRCS
06/26/18
NO CHANGE
Target $430
NRCS
Buy
Align Technology price target raised to $430 from $355 at Northcoast
Northcoast analyst Ed Snyder reiterated a Buy rating and raised his price target on Align Technology to $430 from $355 after completing a monthly review of North American Invisalign doctors, which now exceeds 22,000 total doctors. Snyder tells investors in a research note that Align has seen a nearly 5% shift of doctors from its low-volume bronze tier to its much higher-volume Silver, Gold, Platinum, and Diamond tiers within the last 30 days, and that, as of April 2018, 43.7% of doctors are Bronze, 45.0% are Silver tier, 2.0% are Gold tier, 4.7% are Gold Plus tier, 2.4% are Platinum-tier, and 1.0% are Platinum Plus tier. Snyder raised his FY18 EPS forecast to $5.00 from $4.95 to $5.00 and his FY19 EPS forecast to $6.47 from $6.42 to better reflect improving utilization trends, and expects the company to generate "impressive" internal growth rates, driven by double-digit increases in doctor utilization rates.
ORLY O'Reilly Automotive
$293.35

-0.71 (-0.24%)

07/16/18
FBCO
07/16/18
NO CHANGE
Target $274
FBCO
Neutral
O'Reilly Automotive price target raised to $274 from $246 at Credit Suisse
Credit Suisse analyst Seth Sigman raised his price target for O'Reilly Automotive to $274 from $246 as his channel checks/various data points show that industry trends have improved over the last two months. The analyst reiterates a Neutral rating on the shares.
07/12/18
RBCM
07/12/18
NO CHANGE
Target $319
RBCM
Outperform
O'Reilly Automotive price target raised to $319 from $279 at RBC Capital
RBC Capital analyst Scot Ciccarelli raised his price target on O'Reilly Automotive to $319 and kept his Outperform rating as part of his broader bullish research note on auto parts retail names, saying that favorable weather after a harsh winter/spring and easing headwinds could allow for upside potential in the industry. Ciccarelli adds that his model for O'Reilly Automotive now assumes a 20-times forward twelve-month earnings multiple vs. 17.5-times prior, which is a premium of 15% relative to the market but still below the company's 30% historical premium margin.
06/25/18
MOFT
06/25/18
DOWNGRADE
MOFT
Neutral
O'Reilly Automotive downgraded to Neutral from Buy at MoffettNathanson
06/29/18
BOFA
06/29/18
NO CHANGE
Target $330
BOFA
Buy
O'Reilly can take AutoZone share and withstand Amazon threat, says BofA/Merrill
BofA/Merrill analyst Elizabeth Suzuki is most positive on O'Reilly Automotive (ORLY) in her broader research note on the auto parts retail industry, saying the anticipated repair arc in the U.S. vehicle population favors companies with more exposure to "do it for me" like O'Reilly, Advance Auto Parts (AAP), and Genuine Parts (GPC) rather than "do it yourself" like AutoZone (AZO). The analyst sees Advance Auto Parts pricing in a more optimistic outlook while losing market share and underperforming on margins, rating the company at Underperform with a price target of $103. Suzuki states that Genuine Parts is also constrained by pricing headwinds, rating the company at Neutral with a $105 price target. The analyst likes O'Reilly's expected pace of new store growth, above-average operating margins, and its deepest relative moat through its developed distribution network against a potential threat of entry into the retail auto parts space by Amazon (AMZN), rating the company at Buy with a price target of $330.
XLNX Xilinx
$67.84

0.09 (0.13%)

05/09/18
NOMU
05/09/18
UPGRADE
Target $70
NOMU
Neutral
Xilinx upgraded to Neutral from Reduce at Nomura Instinet
Nomura Instinet analyst Romit Shah upgraded Xilinx to Neutral from Reduce and raised his price target on the stock to $70 from $60.
07/17/18
SUSQ
07/17/18
NO CHANGE
SUSQ
Semi lead-times signal strong demand backdrop, says Susquehanna
Susquehanna analyst Christopher Rolland said his primary research reveals modestly expanding lead times for semis during Q2, suggesting a strong demand backdrop. He also suggested it could be due to some over-ordering and noted they are just below the 2011 peak. The analyst believes Q2 is likely to be solid for the group, but adds that over-ordering risks are growing.
05/14/18
BOFA
05/14/18
NO CHANGE
BOFA
ZTE Corp sanctions relief could benefit semi sales, sentiment, says BofA/Merrill
On Sunday, President Trump's tweet indicates some sanctions relief for China smartphone maker ZTE Corp, BofA/Merrill analyst Vivek Arya wrote in a note to investors. The analyst believes this could be a positive for Skyworks (SEKS), Integrated Device (IDTI), Qorvo (QRVO), Xilinx (XLNX), and Broadcom (AVGO), and clear a path for some recently announced M&A deals.
04/26/18
RHCO
04/26/18
NO CHANGE
Target $72
RHCO
Hold
Xilinx price target lowered to $72 from $79 at SunTrust
SunTrust analyst William Stein lowered his price target on Xilinx (XLNLX) to $72, saying that while the company posted "solid" Q1 earnings and Q2 outlook, the management "confounds" his modeling by deferring the questions regarding the "linearity of datacenter ramp" as well as the size of crypto and ZTE (ZTCOY) import ban until the Analyst Day. Stein keeps his Hold rating, adding that the latest comments do not fit with a more bullish thesis around 5G and server business acceleration.
MHK Mohawk
$218.97

-0.55 (-0.25%)

05/01/18
RBCM
05/01/18
NO CHANGE
Target $284
RBCM
Outperform
Mohawk price target lowered to $284 from $310 at RBC Capital
RBC Capital analyst Michael Eisen lowered his price target on Mohawk to $284, saying that while the company's Q1 results were inline with expectations, the outlook for FY18 regarding accelerating revenue growth and margin expansion was absent. The analyst further notes inefficiencies of new facilities and intensifying startup/input costs but keeps his Outperform rating, noting that the recent weakness does not realize the company's long-term growth prospects.
04/30/18
BARD
04/30/18
NO CHANGE
Target $272
BARD
Outperform
Mohawk price target lowered to $272 from $300 at Baird
Baird analyst Timothy Wojs lowered his price target on Mohawk to $272 from $300 following mixed Q1 results. Wojs reiterated his Outperform rating on Mohawk shares, as he thinks the visibility improves despite lowered estimates, which adds conviction to his expectations for accelerating revenue/EBIT growth in the second half of the year.
04/27/18
LOOP
04/27/18
NO CHANGE
Target $227
LOOP
Hold
Mohawk price target lowered to $227 from $261 at Loop Capital
Loop Capital analyst Laura Champine lowered her price target for Mohawk Industries to $227 citing a weaker margin outlook following the company's Q1 results. The analyst reduced her long term sales growth expectation to 5% from 6% on the rise in interest rates. She reiterates a Hold rating on Mohawk.
06/27/18
RBCM
06/27/18
INITIATION
RBCM
Outperform
Mohawk assumed with an Outperform at RBC Capital
RBC Capital analyst Michael Dahl assumed Mohawk assumed with an Outperform rating and $257 price target. Dahl sees re-accelerating EPS growth in the second half of FY18 and FY19 as ramping LVT capacity, recent price actions, and the Godfrey Hirst acquisition drive improving growth and margins. The analyst also believes that fears of further margin erosion are overblown.
AMD AMD
$16.20

0.01 (0.06%)

07/18/18
SBSH
07/18/18
NO CHANGE
Target $300
SBSH
Buy
Nvidia can selloff near-term on graphics commentary, says Citi
Citi analyst Atif Malik says his recent supply chain checks indicate discrete graphics gaming demand is expected to remain sluggish thru the September quarter due to a "sharp decline" in mining related demand on falling cryptocurrency prices, channel distributors and partners waiting for Nvidia's (NVDA) new Turing gaming card launch in the October quarter, and weak gaming console sales at Microsoft (MSFT) offset by the Nintendo (NTDOY) Switch. The analyst lowered his July and October quarter estimates for Nvidia to bring them in-line with consensus. He thinks the stock can selloff in the near-term on weaker than expected graphics commentary from TSMC (TSM), who reports on July 19, and AMD (AMD), who reports on July 25. Malik, however, keeps a Buy rating on Nvidia with a $300 price target. He believes his long-term thesis on the shares remains intact.
07/13/18
BFIN
07/13/18
NO CHANGE
BFIN
BlueFin says crypto weakness not the only issue for GPU makers
Following an Asian trip to check on semiconductor markets, BlueFin analyst Paul Peterson said his current reads indicate that cryptocurrency market demand remains weak, but this is "not the only thing plaguing the graphics card market." Gamer demand also appears relatively muted, said Peterson, who tells investors in his note that checks indicate GPU card sales dropped by more than 50% in the North America and Europe retail channels. The analyst, who has heard that Nvidia (NVDA) is pressuring retailers to drop their prices, said his work shows graphics card prices have dropped sharply. However, while crypto demand is still weak and overall graphics card sales are sluggish, he thinks data center momentum will be the primary driver for AMD (AMD) and Nvidia stocks in the near-term. Shares of Nvidia are down about 1% to $248.92 in early trading, while AMD has also declined about 1%.
07/17/18
MSCO
07/17/18
NO CHANGE
Target $273
MSCO
Overweight
Negative gaming data for Nvidia largely backward looking, says Morgan Stanley
Morgan Stanley analyst Joseph Moore said he remains positive on Nvidia (NVDA) despite weaker short-term data points in the graphics card market, which have created "significant noise of late." GPU card market weakness is partly reflecting the substantial price increases vendors saw during the cryptocurrency shortage, which should not affect Nvidia's prices, and it is also normal to see channel pullback in front of new product launches, Moore tells investors. He still expects the Turing GPUs to be announced at Gamescom in late August and said spending time with Nvidia management recently has given him confidence. Moore maintains an Overweight rating and $273 price target on Nvidia shares. He adds that he believes AMD (AMD) has gained about 12 points of revenue share in the last 6 quarters, but he foresees a strong rebound in share for Nvidia given its new products and his expectation for no real competitive response from AMD in the next 12 months.
EFX Equifax
$128.01

0.84 (0.66%)

06/25/18
WBLR
06/25/18
NO CHANGE
WBLR
Outperform
Equifax 'Most Improved' at Annual Growth conference, says William Blair
Following the firm's 38th Annual Growth Stock Conference, William Blair analyst Timothy McHugh added Equifax to his "Weekly Top Five" list, telling investors that the stock could be awarded "Most Improved" from the conference as investors walked away "with hope and even confidence" that things are turning around. According to McHugh, Equifax management stated that they are "out of the penalty box" with a majority of their customers, adding that new CEO Mark Begor is being "very aggressive" with personal outreach to these clients and believes the company is willing to be aggressive with pricing if need be. Further, McHugh, has an Outperform rating on Equifax shares, believes it is looking less likely that the company will shut down its U.S. direct-to-consumer business abruptly.
04/10/18
BOFA
04/10/18
INITIATION
Target $115
BOFA
Underperform
Equifax initiated with an Underperform at BofA/Merrill
BofA/Merrill analyst David Ridley-Lane initiated Equifax with an Underperform and$115 price target saying the brand is "impaired" following the 2017 database breach. The analyst said breach will lead to material one-time costs, have lasting damage on the US consumer business, legal settlements, potential legislative and regulatory changes, and possible share losses.
03/29/18
RHCO
03/29/18
NO CHANGE
Target $225
RHCO
Buy
Facebook sell-off is 'overdone', says SunTrust
SunTrust analyst Youssef Squali writes that the 17% decline in the stock price of Facebook (FB) since the emergence of the Cambridge Analytica scandal last week is overdone, keeping his Buy rating and $225 price target. Squali notes that the digital advertisers he spoke with are not leaving the platform because of Facebook's marketing effectiveness and also sees few signs of "users fleeing Facebook en masse". The analyst further points to "compelling valuation" on the shares, the likelihood of limited regulatory actions, and the history of the spillover from other data breach instances impacting companies like Yahoo (AABA) and Equifax (EFX) eventually passing.
04/10/18
04/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Sell at Vertical Group. 2. Philip Morris (PM) initiated with a Buy at Deutsche Bank. 3. Etsy (ETSY) initiated with a Buy at Loop Capital. 4. Zscaler (ZS) initiated with an Outperform at Credit Suisse and Baird, a Strong Buy at Needham, an Equal Weight at Morgan Stanley, Stephens, and Barclays, a Hold at Deutsche Bank, as well as a Neutral at BofA/Merrill and Goldman Sachs. 5. Equifax (EFX) initiated with an Underperform at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
UHS Universal Health
$117.94

3.62 (3.17%)

03/06/18
BARD
03/06/18
NO CHANGE
Target $140
BARD
Outperform
Universal Health price target raised to $140 from $122 at Baird
Baird analyst Whit Mayo raised his price target on Universal Health to $140 from $122 following good Q4 results. The analyst said the results were underpinned by incredibly strong acute growth and improved health plan trends. He noted improved guidance and a clear inflection with the behavioral health side. Mayo reiterated his Outperform rating on Universal Health shares.
07/18/18
GSCO
07/18/18
DOWNGRADE
Target $120
GSCO
Neutral
Universal Health downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Stephen Tanal downgraded Universal Health to Neutral from Buy and cut its price target to $120 from $138 following disappointing results. Tanal said demand for Behavioral Health services remains robust but tight reimbursement rates and strict prior authorization in Medicaid have subdued fundamentals.
05/09/18
MZHO
05/09/18
NO CHANGE
Target $35
MZHO
Buy
Tenet price target raised to $35 from $29 at Mizuho
Mizuho analyst Ann Hynes raised her price target for Tenet Healthcare (THC) to $35 as part of her Hospital model updates following the Q1 earnings season. The analyst reiterates a Buy rating on the shares. She also keeps Buy ratings on HCA Healthcare (HCA) and Universal Health (UHS).
03/05/18
FBCO
03/05/18
NO CHANGE
Target $140
FBCO
Outperform
Universal Health price target raised to $140 from $135 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Universal Health to $140 from $135 on valuation. The analyst reiterates an Outperform rating on the shares.
KNX Knight-Swift
$35.56

0.76 (2.18%)

06/14/18
DBAB
06/14/18
NO CHANGE
DBAB
Buy
Deutsche elevates Knight-Swift to top-pick status, says 'simply too cheap'
After hosting an investor dinner with management Deutsche Bank analyst Amit Mehrotra elevated Knight-Swift (KNX) shares to top-pick status across his entire 35-stock coverage universe, joining XPO Logistics (XPO). Knight-Swift shares are "simply too cheap" based on its prospective earnings growth opportunity, and already discount peak truckload fundamentals in 2019, Mehrotra tells investors in a research note. He sees little downside risk at current share levels, with "free" optionality that the current cycle will be longer and stronger than expectations, which he thinks will be the case.
07/16/18
LEHM
07/16/18
UPGRADE
Target $55
LEHM
Overweight
Knight-Swift upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Brandon Oglenski upgraded Knight-Swift Transportation to Overweight with an unchanged price target of $55.
05/21/18
STFL
05/21/18
UPGRADE
Target $48
STFL
Buy
Knight-Swift upgraded to Buy following selloff at Stifel
As previously reported, Stifel analyst David Ross upgraded Knight-Swift to Buy from Hold, stating that Knight exceeded expectations in Q1 while Swift is getting better and he fully expects the new leadership to improve its operating efficiency. Even though he believes Street estimates are likely still too high, Ross upgraded the stock now given the selloff and underperformance versus peers and his expectation for solid growth in the economy through year-end. Ross has a $48 price target on Knight-Swift shares.
07/16/18
LEHM
07/16/18
UPGRADE
Target $55
LEHM
Overweight
Barclays sees 'appealing opportunity,' upgrades Knight-Swift to Overweight
Barclays analyst Brandon Oglenski upgraded Knight-Swift Transportation to Overweight from Equal Weight with an unchanged price target of $55. Trucking fundamentals should remain "robust" for at least the next few quarters, providing ample opportunity for Knight management to structurally improve profitability in the prior Swift business, Oglenski tells investors in a research note. The analyst sees 35% earnings upside from current levels assuming management can achieve stated synergies along with favorable fundamentals. The stock's underperformance year-to-date creates an "appealing opportunity," Oglenski writes.
MAT Mattel
$16.30

-0.18 (-1.09%)

06/28/18
06/28/18
DOWNGRADE
Target $12

Underperform
Mattel downgraded to Underperform, valuation "out-of-whack," says DA Davidson
As previously reported, DA Davidson analyst Linda Bolton Weiser downgraded Mattel to Underperform citing the +29% run-up in shares from the April 20 lows, despite a lack of improvement in fundamentals. Weiser said Mattel had a difficult Q2 comp due to Cars 3 channel fill, expects light shipments caused by the Toys "R" Us liquidation, and notes plastic resin spot prices are up 30% since late May 2017. As a result, the analyst cut her Q2 earnings estimate to (31c) from (24c), versus consensus of (30c), and reduced her 2018 earnings estimate to (23c) from (16c), and 2019 to 58c from 65c. Weiser views valuation as "out-of-whack" and trimmed her price target to $12 on Mattel shares.
06/28/18
06/28/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AeroVironment (AVAV) downgraded to Hold from Buy at Stifel with analyst Joseph DeNardi citing valuation, but he continues to maintain a positive bias on the stock. 2. Beacon Roofing (BECN) downgraded to Sector Perform from Outperform at RBC Capital with analyst Michael Eisen saying he sees a threat to consensus estimates based on the higher oil price and freight costs amid declining industry demand. 3. Green Plains (GPRE) downgraded to Equal Weight from Overweight at Stephens with analyst Farha Aslam stating that its restructuring plan is a long-term positive, but in the near-term the company may be "forced to cut muscle." 4. Mattel (MAT) downgraded to Underperform from Neutral at DA Davidson with analyst Linda Bolton Weiser noting that the stock price has risen 29% from its April low even though the company's fundamentals have not improved. 5. Aquinox (AQXP) downgraded to Hold from Buy at Needham with analyst Alan Carr noting that the company's Phase 3 trial of rosiptor in Interstitial Cyrstitis failed to demonstrate efficacy, with no evidence of activity at any point or within any subset of patient subset. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here
06/28/18
DADA
06/28/18
DOWNGRADE
DADA
Underperform
Correction: Mattel downgraded to Underperform from Neutral at DA Davidson
06/28/18
DADA
06/28/18
DOWNGRADE
Target $12
DADA
Underperform
Mattel downgraded to Underperform at DA Davidson on impact of TRU liquidation
As reported earlier, DA Davidson analyst Linda Bolton Weiser downgraded Mattel to Underperform from Neutral, keeping her price target at $12. The analyst notes that the stock price has risen 29% from its April low even though the company's fundamentals have not improved. Weiser says Mattel is facing a challenging comps period in Q2 given last year's Cars 3 channel fill, along with the impact and shipment disruptions associated with the bankruptcy of Toys R Us. The analyst also points to higher input costs, with the plastic resin spot prices rising 30% in the past year and 2% since the company last reported Q1 results, anticipating raw material inflation to continue weighing on Mattel's gross margins.

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.